135 related articles for article (PubMed ID: 38287797)
41. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
42. [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
Kida K; Murai M; Yamauchi H
Gan To Kagaku Ryoho; 2017 Feb; 44(2):111-115. PubMed ID: 28223669
[TBL] [Abstract][Full Text] [Related]
43. Identification and Characterization of New
Bouras A; Leone M; Bonadona V; Lebrun M; Calender A; Boutry-Kryza N
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828342
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
45. Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Rizza R; Hackmann K; Paris I; Minucci A; De Leo R; Schrock E; Urbani A; Capoluongo E; Gelli G; Concolino P
Mol Diagn Ther; 2019 Feb; 23(1):121-126. PubMed ID: 30506513
[TBL] [Abstract][Full Text] [Related]
46. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract][Full Text] [Related]
48. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract][Full Text] [Related]
50.
Le TN; Tran VK; Nguyen TT; Vo NS; Hoang TH; Vo HL; Nguyen TT; Nguyen PD; Nguyen VT; Ta TV; Tran HT
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205313
[TBL] [Abstract][Full Text] [Related]
51. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
52. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
[TBL] [Abstract][Full Text] [Related]
53. BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Fanale D; Pivetti A; Cancelliere D; Spera A; Bono M; Fiorino A; Pedone E; Barraco N; Brando C; Perez A; Guarneri MF; Russo TDB; Vieni S; Guarneri G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Apr; 172():103626. PubMed ID: 35150867
[TBL] [Abstract][Full Text] [Related]
54. BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families.
Berzina D; Nakazawa-Miklasevica M; Zestkova J; Aksenoka K; Irmejs A; Gardovskis A; Kalniete D; Gardovskis J; Miklasevics E
BMC Med Genet; 2013 Jun; 14():61. PubMed ID: 23767878
[TBL] [Abstract][Full Text] [Related]
55. Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?
Fanale D; Corsini LR; Pedone E; Randazzo U; Fiorino A; Di Piazza M; Brando C; Magrin L; Contino S; Piraino P; Bazan Russo TD; Cipolla C; Russo A; Bazan V
Crit Rev Oncol Hematol; 2023 Oct; 190():104086. PubMed ID: 37536445
[TBL] [Abstract][Full Text] [Related]
56. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
57. Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma.
Cheng C; Zhou Y; Li H; Xiong T; Li S; Bi Y; Kong P; Wang F; Cui H; Li Y; Fang X; Yan T; Li Y; Wang J; Yang B; Zhang L; Jia Z; Song B; Hu X; Yang J; Qiu H; Zhang G; Liu J; Xu E; Shi R; Zhang Y; Liu H; He C; Zhao Z; Qian Y; Rong R; Han Z; Zhang Y; Luo W; Wang J; Peng S; Yang X; Li X; Li L; Fang H; Liu X; Ma L; Chen Y; Guo S; Chen X; Xi Y; Li G; Liang J; Yang X; Guo J; Jia J; Li Q; Cheng X; Zhan Q; Cui Y
Am J Hum Genet; 2016 Feb; 98(2):256-74. PubMed ID: 26833333
[TBL] [Abstract][Full Text] [Related]
58. Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping.
Neveling K; Mantere T; Vermeulen S; Oorsprong M; van Beek R; Kater-Baats E; Pauper M; van der Zande G; Smeets D; Weghuis DO; Stevens-Kroef MJPL; Hoischen A
Am J Hum Genet; 2021 Aug; 108(8):1423-1435. PubMed ID: 34237281
[TBL] [Abstract][Full Text] [Related]
59. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
60. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
